Multiple Myeloma Clinical Trials
M24-108
A Multicenter, Phase 1b, Open-label Study to Evaluate Dose Optimization Measures and Safety of ABBV-383 in Subjects with Relapsed or Refractory Multiple Myeloma.
MM Trial R5458ONC2245 / LINKER-MM3
Open label phase 3 randomized study designed to evaluate the efficacy and safety of REGN5458 (anti-BCMA x anti-CD3 bispecific antibody) monotherapy vs. the combination in patients with RRMM who have received 1 to 4 lines therapy including a proteasome inhibitor and lenalidomide.